Re:Ozempic Threatens Profits at Food and Beverage Makers Wor...
by wwasilev on Saturday October 21, 2023 @08:08PM
(#37971665)
This is just getting started. VKTX just reported phase 1 results of their GLP1/GIP dual agonist. It appears effective in reducing liver fat (NASH), plasma lipips and weight. The side effects were mild to moderate.
TERN and GPCR are also in the game.